Biologically Active Compounds from Marine Invertebrates 2025

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Chemoecology for Drug Discovery".

Deadline for manuscript submissions: 15 April 2025 | Viewed by 1094

Special Issue Editor


E-Mail Website
Guest Editor
Centro de Investigaciónes Biológicas del Noroeste, La Paz, Baja California Sur, Mexico
Interests: biotechnology; mollusk; antimicrobial; marine natural products
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biologically active compounds derived from marine invertebrates have garnered significant interest from the scientific community due to their vast structural diversity and ability to interact with various biological pathways. These organisms, which inhabit extreme environments and have developed unique defense and survival mechanisms, are an invaluable source of secondary metabolites with therapeutic potential. Among their most studied properties are antimicrobial, anti-inflammatory, and anticancer activities, positioning marine invertebrates as a key focus in the search for novel pharmaceutical agents.

The focus of the included articles should be to highlight the potential of bioactive compounds from marine invertebrates, emphasizing their diversity in molecular targets and mechanistic effects. Additionally, approaches describing synergistic combination treatments of these marine compounds with clinically used or experimental therapeutic agents will be welcomed, aiming to enhance the efficacy and application of these bioactive molecules in various biomedical fields.

For this Special Issue, we invite academic scientists to submit comprehensive reviews and original research articles focusing on biologically active compounds derived from marine invertebrates. These compounds have shown significant potential in various fields, including pharmaceuticals, biotechnology, and biomedical sciences, due to their unique chemical structures and diverse bioactivities. We welcome contributions that explore the discovery of novel compounds, mechanisms of action, bioassays, and potential applications.

Dr. Crisalejandra Rivera-Pérez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioactive compounds
  • antimicrobial
  • antioxidants
  • anticancerogenic
  • angiotensin activity
  • biomedicine
  • biotechnology
  • marine natural products

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 1783 KiB  
Article
New Polyhydroxysteroid Glycosides with Antioxidant Activity from the Far Eastern Sea Star Ceramaster patagonicus
by Timofey V. Malyarenko, Viktor M. Zakharenko, Alla A. Kicha, Arina I. Ponomarenko, Igor V. Manzhulo, Anatoly I. Kalinovsky, Roman S. Popov, Pavel S. Dmitrenok and Natalia V. Ivanchina
Mar. Drugs 2024, 22(11), 508; https://doi.org/10.3390/md22110508 - 10 Nov 2024
Viewed by 749
Abstract
Four new glycosides of polyhydroxysteroids, ceramasterosides A, B, D, and E (14), and two previously known compounds, ceramasteroside C1 (5) and attenuatoside B-I (6), were isolated from an extract of a deep-sea sea star [...] Read more.
Four new glycosides of polyhydroxysteroids, ceramasterosides A, B, D, and E (14), and two previously known compounds, ceramasteroside C1 (5) and attenuatoside B-I (6), were isolated from an extract of a deep-sea sea star species, the orange cookie star Ceramaster patagonicus. The structures of 14 were elucidated by the extensive NMR and ESIMS methods. Steroid monoglycosides 1 and 2 had a common 3β,6α,8,15β,16β-pentahydroxysteroid nucleus and a C–29 oxidized stigmastane side chain and differed from each other only in monosaccharide residues. Ceramasteroside A (1) contained 3-O-methyl-4-O-sulfated β-D-xylopyranose, while ceramasteroside B (2) had 3-O-methyl-4-O-sulfated β-D-glucopyranose, recorded from starfish-derived steroid glycosides for the first time. Their biological activity was studied using a model of lipopolysaccharide-induced (LPS) inflammation in a SIM-A9 murine microglial cell line. During the LPS-induced activation of microglial cells, 1, 3, and 5, at a non-toxic concentration of 1 µM, showed the highest efficiency in reducing the production of intracellular NO, while 4 proved to be most efficient in reducing the extracellular nitrite production. All the test compounds reduced the LPS-induced malondialdehyde (MDA) production. The in vitro experiments have demonstrated, for the first time, the antioxidant activity of the compounds under study. Full article
(This article belongs to the Special Issue Biologically Active Compounds from Marine Invertebrates 2025)
Show Figures

Graphical abstract

Back to TopTop